IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

TRAPANI, DARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.025
AS - Asia 5.373
NA - Nord America 4.436
SA - Sud America 552
AF - Africa 135
OC - Oceania 43
Continente sconosciuto - Info sul continente non disponibili 9
Totale 16.573
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.219
DE - Germania 2.854
CN - Cina 1.733
SG - Singapore 1.537
IT - Italia 1.045
HK - Hong Kong 521
VN - Vietnam 470
BR - Brasile 436
SE - Svezia 390
RU - Federazione Russa 363
GB - Regno Unito 362
FR - Francia 288
IN - India 259
BD - Bangladesh 227
NL - Olanda 164
FI - Finlandia 138
CA - Canada 118
JP - Giappone 116
IE - Irlanda 98
TR - Turchia 93
ID - Indonesia 84
KR - Corea 80
ES - Italia 59
MX - Messico 56
AT - Austria 49
CI - Costa d'Avorio 48
CH - Svizzera 44
PL - Polonia 38
PH - Filippine 37
AR - Argentina 35
TW - Taiwan 34
AU - Australia 33
ZA - Sudafrica 29
IQ - Iraq 26
DK - Danimarca 24
EC - Ecuador 23
BE - Belgio 22
CO - Colombia 20
UA - Ucraina 17
PK - Pakistan 16
TH - Thailandia 16
IR - Iran 14
SA - Arabia Saudita 13
EG - Egitto 12
JO - Giordania 12
TN - Tunisia 11
VE - Venezuela 11
AE - Emirati Arabi Uniti 10
KE - Kenya 10
MY - Malesia 10
UZ - Uzbekistan 10
AZ - Azerbaigian 9
CZ - Repubblica Ceca 9
NZ - Nuova Zelanda 9
CL - Cile 8
GR - Grecia 8
IL - Israele 8
JM - Giamaica 8
TT - Trinidad e Tobago 8
KZ - Kazakistan 7
MA - Marocco 7
PE - Perù 7
AP - ???statistics.table.value.countryCode.AP??? 6
DZ - Algeria 6
PT - Portogallo 6
RO - Romania 6
SK - Slovacchia (Repubblica Slovacca) 6
PS - Palestinian Territory 5
PY - Paraguay 5
CY - Cipro 4
DO - Repubblica Dominicana 4
GE - Georgia 4
LT - Lituania 4
MD - Moldavia 4
NI - Nicaragua 4
OM - Oman 4
UY - Uruguay 4
BG - Bulgaria 3
BH - Bahrain 3
CR - Costa Rica 3
ET - Etiopia 3
HN - Honduras 3
HR - Croazia 3
HU - Ungheria 3
LB - Libano 3
LU - Lussemburgo 3
LV - Lettonia 3
NO - Norvegia 3
AL - Albania 2
BO - Bolivia 2
BS - Bahamas 2
BZ - Belize 2
EE - Estonia 2
GA - Gabon 2
GT - Guatemala 2
NG - Nigeria 2
NP - Nepal 2
PA - Panama 2
PR - Porto Rico 2
SC - Seychelles 2
Totale 16.551
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 2.592
Singapore 749
Ashburn 576
Hong Kong 438
Dallas 328
San Jose 317
Milan 292
Hefei 267
Chandler 235
Southend 216
Council Bluffs 200
Beijing 198
Ho Chi Minh City 149
Los Angeles 148
Santa Clara 128
New York 114
Bengaluru 99
Hanoi 96
Dublin 95
Lauterbourg 93
Fairfield 90
Helsinki 89
Moscow 88
Shanghai 88
Princeton 83
Rome 78
Guangzhou 76
Boardman 72
Buffalo 67
Houston 65
Seoul 58
Wilmington 56
Istanbul 54
Jakarta 53
Munich 53
Redwood City 52
Tokyo 51
Abidjan 48
São Paulo 48
Dearborn 42
Cangzhou 37
Hyderabad 37
Naples 37
Seattle 37
Chicago 36
Columbus 34
London 34
Cambridge 33
Des Moines 33
Toronto 32
Woodbridge 32
Vienna 30
Amsterdam 29
Nanjing 29
Turin 29
Atlanta 28
Lappeenranta 28
Shenyang 28
Hangzhou 25
Da Nang 24
Düsseldorf 24
Philadelphia 24
Dong Ket 23
Paris 23
Boston 22
Phoenix 22
Ann Arbor 21
Zhengzhou 21
Montreal 20
Wuhan 20
Nuremberg 19
Rio de Janeiro 18
Bari 17
Changsha 17
Jinan 17
Tianjin 17
Washington 17
Genoa 16
Sydney 16
Taipei 16
Berlin 15
Bologna 15
Florence 15
Fuzhou 15
San Diego 15
Verona 15
Brussels 14
Haiphong 14
Mumbai 14
Shenzhen 14
Turku 14
Ankara 13
Manchester 13
Stockholm 13
Denver 12
Guayaquil 12
Manila 12
Mexico City 12
Orem 12
Palermo 12
Totale 9.934
Salva come PNG Salva come JPEG
Nome #
Entinostat for the treatment of breast cancer 897
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer : a systematic review 764
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 514
European Society for Medical Oncology (ESMO) 2018 Congress Twitter analysis : From ethics to results through the understanding of communication and interaction flows 506
Expression of tumor-associated antigens in breast cancer subtypes 318
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure 317
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 245
Grading of recommendations, assessment, development and evaluations concept 7: issues and insights linking guideline recommendations to trustworthy essential medicine lists 239
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer 224
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer 223
Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy 217
How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer : Between Biomarkers and Novel Cell-Based Approaches 217
Liver toxicity in the era of immune checkpoint inhibitors: A practical approach 216
Evolution of low HER2 expression between early and advanced-stage breast cancer 214
Master protocols in immuno-oncology : Do novel drugs deserve novel designs? 213
Assessing Population Diversity in Phase III Trials of Cancer Drugs Supporting FDA Approval in Solid Tumors 209
Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact 207
The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review 204
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer 198
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 197
Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology 195
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer 191
Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life 191
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer 190
Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives 184
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus 183
First line treatment of BRAF mutated advanced melanoma: Does one size fit all? 181
Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials 180
Biomarkers for antibody-drug conjugates in solid tumors 178
The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy 176
Adjuvant treatment of early male breast cancer 168
Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates 166
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 165
An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer 164
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations 163
Primary malignant phyllodes tumors of the breast: A retrospective analysis from a referral center 163
The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region 161
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring 160
Targeting the microenvironment in solid tumors 159
ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer 158
Distribution of the workforce involved in cancer care: a systematic review of the literature 158
Genomic analysis of circulating tumor DNA to predict endocrine resistance and clonal evolution in patients with prostate cancer : clinical perspectives and research opportunities 155
Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy 150
Repurposing anticancer drugs for the management of COVID-19 149
Evaluating triptorelin as a treatment option for breast cancer 147
Cardiotoxicity of Agents Used in Patients With Breast Cancer 145
ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0 144
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents 144
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments 143
Molecular tumor board in patients with metastatic breast cancer 142
Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–related disease pandemic 141
Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations 141
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment 139
Screening Programs for Breast Cancer: Toward Individualized, Risk-Adapted Strategies of Early Detection 137
Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement 137
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology 135
Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer 133
A conceptual framework for cautious escalation of anticancer treatment: How to optimize overall benefit and obviate the need for de-escalation trials 132
The pathologic and genomic evolution of primary malignant phyllodes tumors of the breast: retrospective cohort study and case-control genomic analysis 129
Pharmacological management of male breast cancer 129
Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence 128
Cancer in Transgender and Gender-Diverse Persons: A Review 127
The immunogram of inflammatory breast cancer 127
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases 126
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study 126
WHO model list of essential in vitro diagnostics: strengthening diagnostics capacity to transform health care for all 126
National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis 125
How to treat lobular cancer in the adjuvant setting? 124
The global landscape of treatment standards for breast cancer 124
Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms 122
Global challenges and policy solutions in breast cancer control 122
Benefit of adjuvant chemotherapy in patients with lobular breast cancer : A systematic review of the literature and metanalysis 121
Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021 119
The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality 118
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies 117
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit 117
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan 115
Strategies to modulate the immune system in breast cancer : checkpoint inhibitors and beyond 114
Management of Cardiac Toxicity Induced by Chemotherapy 114
Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems 111
Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study 110
Establishing a Lancet Oncology Commission on the humanitarian crisis of cancer 107
How can biosimilars change the trajectory of breast cancer therapy? 107
Common Sense Oncology: outcomes that matter 106
COVID-19 vaccines in patients with cancer 106
Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer 105
The global landscape of drug development for kidney cancer 103
Impact of Prior Authorization on Patient Access to Cancer Care 99
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability 98
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer 95
PARP inhibitor resistant BRCA-mutated advanced breast cancer: current landscape and emerging treatments 94
Adjuvant Chemotherapy in Older Women With Early Breast Cancer 91
Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go? 91
Policy strategies for capacity building and scale up of the workforce for comprehensive cancer care: a systematic review 88
The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations 86
The rise of immuno-oncology in China: a challenge to western dominance? 83
Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer 77
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study 75
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials 61
Mastering the Use of Novel Anti-HER2 Treatment Options 61
Totale 16.911
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.199
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.199
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021262 0 0 0 0 0 0 0 0 0 0 106 156
2021/2022806 70 89 59 56 64 83 49 46 92 38 44 116
2022/2023969 94 92 113 90 75 160 30 66 102 22 87 38
2023/20242.576 40 76 42 79 154 105 311 278 181 339 454 517
2024/20254.166 480 488 446 383 169 142 112 314 211 346 339 736
2025/20267.363 763 717 895 662 481 348 876 352 636 472 1.161 0
Totale 17.100